Life Sciences - Investment Banking Group

Life Sciences

The Indian Life Sciences sector is currently estimated at US$ 34 billion and is expected to more than double to US$ 78 billion over the next few years.

India has a strong presence in generic drugs manufacturing, and is one of the largest exporters of generic drugs in the world. Outside the USA, India has the largest number of USA FDA approved manufacturing plants, reinforcing the perception that India is a quality producer of pharmaceutical products. Major multinational pharmaceutical companies have set up operations in India, offering their products to the burgeoning middle class. Indian companies, in turn, are going global and setting up operations in the USA, Europe, Africa and Japan.

With the growth in disposable incomes and changing lifestyles, there is a significant unmet demand for quality Life Sciences from the middle class in India. Large corporations have set up or are setting a large number of specialty hospitals to fill this void.

o3 Capital has wide experience in executing cross-border mergers and acquisitions and private equity syndication transactions in various segments, including the pharmaceutical and Life Sciences services. We offer clients in-depth domain knowledge and unparalleled execution skills.